Global Brown-Sequard Syndrome Treatment Market, By Type (Traumatic BSS and non- Traumatic BSS), Treatment (Devices, Medications), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Brown-Sequard Syndrome Treatment Market
Brown-Sequard syndrome treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.90% in the above-mentioned research forecast period. Increasing number of traumatic injuries worldwide and growing number of vertebral disc- herniation, cervical spondylosis, tumors, multiple sclerosis, among others.
Rising cases of spinal cord injuries and technological advancements for appropriate diagnosis also boost up the market growth. Moreover, increasing partnership and collaboration among market players and increasing demand of effective therapies and drugs act as opportunity for the market growth. But, lack of disease awareness, drugs liability and strict regulations may hamper the global Brown-Sequard syndrome treatment market.
Brown- Sequard syndrome is one of the neurological diseases which can be differentiated by the formation of lesions in spinal cord. The lesion formation results in paralysis (hemiparaplegia) or weakness on one side of the affected individual. Brown- Sequard syndrome can be caused by both the traumatic injuries and non- traumatic injuries. The most common traumatic injuries associated with BSS includes puncture wound to the back or neck among others. Inflammatory, infectious diseases, ischemia, tuberculosis, multiple sclerosis among others are few other diseases responsible for BSS. BSS caused by traumatic injuries can be diagnosed by X- ray or MRI, however in case of infectious etiologies purified protein derivative and sputum is frequently used so as to confirm the disease symptoms. Decompression surgery is most commonly preferred for BSS associated with trauma or tumor. In most of the BSS cases caused by infectious and other types of diseases, standard perioperative prophylactic antibiotics are recommended. Cervical collars and spinal orthosis are also used for treatment of BSS associated with neck or thoracolumbar region.
Increasing geriatric population is more prone to spinal cord injuries and cancer. As per the publication of NCBI the overall global incidence of traumatic spinal cord injuries was 10.5 cases per 100,000 people in 2018 and the maximum number of cases reported in low and middle income countries. This increasing number of traumatic injuries has posed the demand for effective therapies hence expected to provide market with the lucrative growth.
This Brown-Sequard syndrome treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Brown-Sequard Syndrome Treatment Market Scope and Market Size
Brown-Sequard syndrome treatment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the Brown-Sequard syndrome treatment market is segmented into traumatic BSS and non- traumatic BSS.
- On the basis of treatment, the Brown-Sequard syndrome treatment market is segmented into devices and medication. Devices segment is further sub- segmented into hard-collar, gardner wells tongs among others. Medication segment is further sub- segmented into perioperative prophylactic antibiotics, antispasmodics, pain medication and laxatives.
- On the basis of route of administration, the Brown-Sequard syndrome treatment market is segmented into oral, parenteral, others.
- On the basis of end-users, the Brown-Sequard syndrome treatment market is segmented into clinics, hospitals, homecare, others.
- On the basis of distribution channel, the Brown-Sequard syndrome treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Brown-Sequard syndrome treatment Market Country Level Analysis
Brown-Sequard syndrome treatment market is analysed and market size information is provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Brown-Sequard syndrome treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to rising number of geriatric patients and increasing prevalence of traumatic spinal injuries. Europe accounts the second largest market share due to enhanced product distribution network and increasing cases of non-traumatic cases including multiple sclerosis among others, as number of reported MS cases in Europe estimated to be 83 per 100,000 population with higher number of cases reported in northern area. Asia-Pacific is expected to account for the largest market share over coming years for the Brown-Sequard syndrome treatment market due to increasing demand of effective therapies and increasing investment for development of innovative devices.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Brown-Sequard syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Brown-Sequard syndrome treatment Market Share Analysis
Brown-Sequard syndrome treatment market competitive landscape provides details by competitor, details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Brown-Sequard syndrome treatment market.
The major players covered in the Brown-Sequard syndrome treatment market are Pfizer Inc., B. Braun Medical Inc., Sandoz Canada Inc., Aurobindo Pharma Limited, Fresenius Kabi Canada, Hikma, AdvaCare Pharma, SteriMax, Baxter Healthcare, Stanex, Xellia Pharmaceuticals, Concord Biotech, Abbott, Bayer AG, Tynorindia, Integra LifeSciences Corporation, ERREGIERRE S.p.A., Alchem International Pvt. Ltd. among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
